Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL)

Bone Marrow Transplantation

Volumn 26, Issue 9, 2000, Pages 963-969

  Gertz, M A ^a   Lacy, M Q ^a   Gastineau, D A ^a   Inwards, D J ^a   Chen, M G ^a   Tefferi, A ^a   Kyle, R A ^a   Litzow, M R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyloidosis; Congestive heart failure; Monoclonal protein; Multiple myeloma; Nephrotic syndrome; Stem cell transplantation

Indexed keywords

MELPHALAN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART AMYLOIDOSIS; HEART VENTRICLE SEPTUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HUMAN; KIDNEY AMYLOIDOSIS; LIVER DISEASE; MALE; MORBIDITY; MORTALITY; NEPHROTIC SYNDROME; PERIPHERAL NEUROPATHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SURVIVAL; THICKNESS; WHOLE BODY RADIATION;

EID: 0033758844     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702643     Document Type: Article

References (28)

1. Amyloidosis: A final common pathway for protein deposition in tissues
2. Regression of amyloidosis in multiple myeloma
3. Intensive chemotherapy for AL amyloidosis
4. Response rates and survival in primary systemic amyloidosis
5. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only
6. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine
7. Allogeneic bone marrow transplantation for systemic AL amyloidosis
8. Allogeneic bone marrow transplantation for AL amyloidosis
9. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis
10. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: Survival and responses in 25 patients
11. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: A report on 21 patients
12. Factors influencing platelet recovery after blood cell transplantation in multiple myeloma
13. Autotransplants in multiple myeloma: Pushing the envelope
14. Primary systemic amyloidosis: Comparison of melphalan and prednisone versus placebo
15. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation
16. Primary systemic amyloidosis: Clinical and laboratory features in 474 cases
17. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
18. Multiple myeloma
19. High-dose melphalan and autologous bone marrow transplantation for systemic AL amyloidosis with cardiac involvement
20. Intensive therapy in AL amyloidosis and light-chain deposition disease
21. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients
22. High dose melphalan for AL amyloidosis: Outcomes in 50 patients
23. High-dose melphalan and stem cell rescue for AL amyloidosis
24. Gastrointestinal perforation early after peripheral blood stem cell transplantation for AL amyloidosis
25. Morbidity associated with high dose therapy in primary amyloidosis
26. + cells selected as autografts in patients with primary light-chain amyloidosis: Rationale and application
27. Fatal cardiac failure after a single dose of doxorubicin in myeloma-associated cardiac amyloid
28. The diagnosis, natural history and treatment of amyloidosis